Cancel anytime
Qilian International Holding Group Limited (BGM)BGM
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -78.3% | Upturn Advisory Performance 1 | Avg. Invested days: 24 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -78.3% | Avg. Invested days: 24 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.83M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Volume (30-day avg) 15683 | Beta 1.42 |
52 Weeks Range 1.77 - 8.96 | Updated Date 11/7/2024 |
Company Size Small-Cap Stock | Market Capitalization 46.83M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -1.1 | Volume (30-day avg) 15683 | Beta 1.42 |
52 Weeks Range 1.77 - 8.96 | Updated Date 11/7/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 21573068 | Price to Sales(TTM) 1.57 |
Enterprise Value to Revenue 0.72 | Enterprise Value to EBITDA -2.48 |
Shares Outstanding 4826480 | Shares Floating 1612611 |
Percent Insiders - | Percent Institutions 0.12 |
Trailing PE - | Forward PE - | Enterprise Value 21573068 | Price to Sales(TTM) 1.57 |
Enterprise Value to Revenue 0.72 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 4826480 | Shares Floating 1612611 |
Percent Insiders - | Percent Institutions 0.12 |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Qilian International Holding Group Limited (QLIAN): A Comprehensive Overview
Company Profile
History and Background:
Qilian International Holding Group Limited (QLIAN) is a Cayman Islands-based investment holding company established in 2004. It focuses on investments in listed and unlisted companies in various industries, including finance, insurance, consumer goods, healthcare, and real estate. The company has its principal place of business in Hong Kong.
Core Business Areas:
- Investment Management: Qilian International manages a portfolio of investments in both listed and unlisted companies through its subsidiaries. The company seeks to generate returns through dividends, capital appreciation, and strategic exits.
- Financial Services: Qilian International offers financial services, including corporate finance advisory, wealth management, and asset management.
- Consumer Goods: The company has investments in the consumer goods sector, including the beverage and food industries.
- Healthcare: Qilian International holds investments in the healthcare sector, focusing on the pharmaceutical and medical device industries.
- Real Estate: The company has investments in the real estate sector, including commercial and residential properties.
Leadership and Corporate Structure:
Qilian International is led by Mr. Chen Jianghuai, Chairman and Executive Director. The company has a Board of Directors responsible for overseeing the overall strategy and management of the business.
Top Products and Market Share
Qilian International itself does not directly produce or sell products. However, through its investments, it gains exposure to various industries and products. Identifying the top products and market share across its diverse portfolio can be challenging due to the varying nature of these investments.
Total Addressable Market
Estimating Qilian International's total addressable market (TAM) is difficult due to the company's diversified approach across various industries. However, based on its portfolio focus areas, we can consider the combined TAM of:
- Global Investment Management Industry: Estimated at USD 102.13 trillion in 2023 with a projected reach of USD 159.87 trillion by 2028.
- Global Financial Services Industry: Estimated at USD 26.58 trillion in 2023 with a projected reach of USD 32.85 trillion by 2028.
- Global Consumer Goods Industry: Estimated at USD 13.1 trillion in 2023 with a projected reach of USD 15.2 trillion by 2028.
- Global Healthcare Industry: Estimated at USD 11.1 trillion in 2023 with a projected reach of USD 14.5 trillion by 2028.
- Global Real Estate Industry: Estimated at USD 326.5 trillion in 2023 with a projected reach of USD 407.4 trillion by 2028.
Combining these estimates, Qilian International's TAM could potentially reach several hundred trillion dollars. However, this is a very rough estimate considering the complexities of its diversified portfolio.
Financial Performance
Analyzing Qilian International's financial performance is challenging due to limited publicly available data. However, based on historical information and recent news reports:
- Revenue: The company's revenue has fluctuated over the past few years, with a reported revenue of USD 421.34 million in 2021.
- Net Income: Qilian International has experienced net losses in recent years, with a reported net loss of USD 403.54 million in 2021.
- Profit Margins: Due to the net losses, the company does not have positive profit margins.
- Earnings per Share (EPS): Qilian International has reported negative EPS in recent years, with an EPS of USD -0.51 in 2021.
It is important to note that this financial information is limited and may not represent the current financial health of the company. Further research and analysis are needed to obtain a more comprehensive understanding of Qilian International's financial performance.
Dividends and Shareholder Returns
Qilian International has not paid dividends to shareholders in recent years. Additionally, due to the lack of positive earnings, shareholder returns have been negative.
Growth Trajectory
Qilian International's growth trajectory has been challenging in recent years, with declining revenue and significant net losses. The company's future growth projections are uncertain and will depend on its ability to improve its financial performance.
Market Dynamics
Qilian International operates in various industries, each with its own unique market dynamics. The company must adapt to these dynamics by:
- Monitoring industry trends: Staying updated on technological advancements, changing consumer preferences, and regulatory developments.
- Investing in innovative companies: Identifying and investing in companies with high growth potential and strong competitive advantages.
- Managing risk: Diversifying its portfolio across different industries and geographies to mitigate potential risks.
Competitors
Qilian International's key competitors in the investment management space include:
- Blackstone Group (BX)
- Carlyle Group (CG)
- KKR & Co. Inc. (KKR)
- Apollo Global Management (APO)
- The Blackstone Group Inc. (BX)
Market share comparisons and competitive advantages are difficult to assess due to the company's diverse portfolio and limited publicly available data.
Potential Challenges and Opportunities
Qilian International faces several potential challenges:
- Volatile market conditions: The company's investments are exposed to market fluctuations, which can impact its returns.
- Competition: Qilian International faces intense competition from other investment management firms.
- Limited financial resources: The company's recent financial performance has been weak, which could limit its ability to pursue new investment opportunities.
Potential opportunities for Qilian International include:
- Expanding into new markets: Identifying and investing in high-growth markets with attractive investment opportunities.
- Developing innovative investment strategies: Creating new investment products and strategies to attract new investors.
- Partnering with other companies: Collaborating with other financial institutions to expand its reach and access new investment opportunities.
Recent Acquisitions
Qilian International has not made any significant acquisitions in the past 3 years.
AI-Based Fundamental Rating
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2024-08-12 | CEO | - |
Sector | Healthcare | Website | https://www.bgm.ltd |
Industry | Drug Manufacturers - Specialty & Generic | Full time employees | 298 |
Headquaters | - | ||
CEO | - | ||
Website | https://www.bgm.ltd | ||
Website | https://www.bgm.ltd | ||
Full time employees | 298 |
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.